Advanced Care for Metastatic and Recurrent Breast Cancer in Shanghai
A diagnosis of recurrent or metastatic breast cancer — cancer that has returned after initial treatment or spread to other organs such as the liver, lungs, bones, or brain — is one of the most challenging situations a patient can face. While metastatic breast cancer (MBC) is not currently curable in most cases, it is increasingly treatable as a chronic condition, with patients achieving years of high-quality life through precision systemic therapy. Shanghai is home to specialists who see more advanced breast cancer patients than almost anywhere else in the world.
Featured Specialist: Prof. Wang Hongxia (王红霞)
Prof. Wang Hongxia is a leading medical oncologist at Fudan University Shanghai Cancer Center (FUSCC), specializing in the precision treatment of recurrent and metastatic breast cancer and immunotherapy for solid tumors.
Prof. Wang is a recipient of the National Outstanding Youth Science Fund (National Jieqing / 国家杰青) — China's most competitive grant for outstanding young scientists — and the Chinese Young Women in Science Award (中国青年女科学家奖), recognizing her as one of China's most accomplished female researchers in oncology.
Her clinical volume is exceptional: Prof. Wang's team treats over 500,000 patient visits per year for recurrent and metastatic breast cancer — giving her team unparalleled experience with the full spectrum of advanced disease presentations, treatment sequences, and resistance patterns.
Precision Treatment for Metastatic Breast Cancer
The treatment of metastatic breast cancer has been transformed by molecular profiling and targeted therapy. Prof. Wang's approach is built on identifying the specific biological drivers of each patient's cancer and matching them to the most effective available therapy:
HR+/HER2− Metastatic Breast Cancer
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy — the current standard of care for first-line HR+ MBC
- PI3K/AKT/mTOR pathway inhibitors for endocrine-resistant disease
- Antibody-drug conjugates (ADCs) such as sacituzumab govitecan for later-line therapy
- ESR1 mutation-guided therapy — molecular testing to detect resistance mutations and switch endocrine agents accordingly
HER2-Positive Metastatic Breast Cancer
- Dual HER2 blockade (trastuzumab + pertuzumab) with chemotherapy
- T-DM1 and T-DXd (trastuzumab deruxtecan) — next-generation HER2-targeted ADCs with remarkable response rates
- Tucatinib-based regimens for HER2+ MBC with brain metastases
- Lapatinib and neratinib combinations for later-line HER2+ disease
Triple-Negative Metastatic Breast Cancer
- Immunotherapy (PD-1/PD-L1 inhibitors) combined with chemotherapy for PD-L1-positive TNBC
- PARP inhibitors (olaparib, niraparib) for BRCA1/2-mutated TNBC
- Sacituzumab govitecan — Trop-2-targeted ADC with significant survival benefit in refractory TNBC
- Fudan Classification-guided therapy in collaboration with Prof. Jiang Yizhou's team at FUSCC
Immunotherapy for Solid Tumors
Beyond breast cancer, Prof. Wang's research extends to immunotherapy for solid tumors more broadly — including the mechanisms of immune evasion, biomarker identification for immunotherapy response, and novel combination strategies. Patients with complex or refractory solid tumor presentations may benefit from her expertise in immune-oncology beyond standard protocols.
Managing Metastatic Sites
Metastatic breast cancer requires coordinated management of both systemic disease and specific metastatic sites. At FUSCC, Prof. Wang works within a multidisciplinary team to address:
- Bone metastases: Bisphosphonates, denosumab, and radiation for pain control and fracture prevention
- Liver metastases: Systemic therapy optimization; interventional radiology for selected cases
- Lung metastases: Systemic therapy; pulmonology co-management
- Brain metastases: Stereotactic radiosurgery coordination; HER2-targeted CNS-penetrant agents (tucatinib, T-DXd)
- Leptomeningeal disease: Intrathecal therapy and CNS-directed systemic agents
Who Should Consider Consulting Prof. Wang?
- Patients with newly diagnosed metastatic breast cancer seeking a precision treatment plan
- Patients whose cancer has progressed on standard therapy and need next-line options
- Patients seeking access to clinical trials for novel agents at FUSCC
- Patients with brain or leptomeningeal metastases requiring specialized systemic management
- Patients wanting a second opinion on their current metastatic breast cancer treatment plan
- Patients with rare or complex MBC presentations requiring high-volume specialist experience
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We connect international patients with Shanghai's leading oncologists, including Prof. Wang Hongxia at Fudan University Shanghai Cancer Center, and manage every step of the process:
- Review of existing pathology, molecular profiling reports, imaging, and treatment history
- Specialist referral to Prof. Wang's medical oncology team
- Coordination of additional molecular testing (NGS, ESR1, PD-L1, HER2 re-testing) if needed
- Appointment scheduling with priority access
- Medical interpretation during consultations and tumor board discussions
- Logistics support: accommodation, visa assistance, and local transport
- Post-consultation follow-up and remote monitoring coordination
Get in Touch
If you or a family member has been diagnosed with recurrent or metastatic breast cancer and are exploring treatment options in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 Kommentare